Visceral leishmaniasis (VL) is a rare disease in renal transplant recipients. Liposomal amphotericin B (AmBisome) is known to be effective against VL.
Kostakis +6 more
core
Visceral leishmaniasis is a worldwide, disseminated intracellular protozoal infection that usually manifests by fever, hepatosplenomegaly, anemia, thrombocytopenia, leukopenia and hypergammaglobulinemia. Although anemia is a usual finding, Coombs'
Embiya Dilber +2 more
doaj
Liposomal amphotericin B-the future. [PDF]
Hoenigl M +4 more
europepmc +1 more source
First Infant Desensitization to Liposomal Amphotericin B. [PDF]
Rostamyan M +3 more
europepmc +1 more source
Liposomal amphotericin B-associated electrolyte abnormalities among adult patients in a tertiary hospital. [PDF]
Himali NA +6 more
europepmc +1 more source
Liposomal amphotericin B as an antifungal prophylaxis in bilateral lung transplantation: a safety analysis. [PDF]
Boscolo A +13 more
europepmc +1 more source
Liposomal amphotericin B in the treatment of pediatric gastrointestinal basidiobolomycosis. [PDF]
Forooghi M +5 more
europepmc +1 more source
Nebulized Liposomal Amphotericin B as an Alternative Therapy for an <i>Aspergillus</i> Tracheal Plaque. [PDF]
Valdes-Camacho S +9 more
europepmc +1 more source
Can liposomal amphotericin B be used as a preventive measure for cryptococcal meningitis? [PDF]
Schwartz EL, Bahr NC, Rajasingham R.
europepmc +1 more source
Non-Interventional, Retrospective, Multicenter Study on the Renal Safety of Liposomal Amphotericin B in Critically Ill Patients with Invasive Pulmonary Aspergillosis. [PDF]
Suberviola B +7 more
europepmc +1 more source

